These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 33256901)

  • 1. New approaches to the treatment of older adults with acute lymphoblastic leukemia.
    Schwartz M; Wieduwilt MJ
    Semin Hematol; 2020 Jul; 57(3):122-129. PubMed ID: 33256901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.
    Jabbour E; Short NJ; Jain N; Haddad FG; Welch MA; Ravandi F; Kantarjian H
    J Hematol Oncol; 2023 Mar; 16(1):22. PubMed ID: 36927623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How should we treat older adults with Ph+ adult ALL and what novel approaches are being investigated?
    Wieduwilt MJ
    Best Pract Res Clin Haematol; 2017 Sep; 30(3):201-211. PubMed ID: 29050693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SOHO State of the Art Updates and Next Questions | Approach to Older Adults With Phildadelphia-Chromosome Negative Acute Lymphoblastic Leukemia.
    Shimony S; Luskin MR
    Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):133-140. PubMed ID: 38102012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute Lymphoblastic Leukemia in the Older Adult.
    Aldoss I; Forman SJ; Pullarkat V
    J Oncol Pract; 2019 Feb; 15(2):67-75. PubMed ID: 30763199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal approach to the treatment of young adults with acute lymphoblastic leukemia in 2020.
    Rank CU; Schmiegelow K
    Semin Hematol; 2020 Jul; 57(3):102-114. PubMed ID: 33256899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.
    Marks DI; Kebriaei P; Stelljes M; Gökbuget N; Kantarjian H; Advani AS; Merchant A; Stock W; Cassaday RD; Wang T; Zhang H; Loberiza F; Vandendries E; DeAngelo DJ
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1720-1729. PubMed ID: 31039409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation and management of measurable residual disease in acute lymphoblastic leukemia.
    Abou Dalle I; Jabbour E; Short NJ
    Ther Adv Hematol; 2020; 11():2040620720910023. PubMed ID: 32215194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
    Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
    Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens.
    Short NJ; Kantarjian H; Jabbour E
    Leuk Lymphoma; 2024 Jun; ():1-13. PubMed ID: 38850572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.
    Jabbour E; Pui CH; Kantarjian H
    JAMA Oncol; 2018 Oct; 4(10):1413-1420. PubMed ID: 29931220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innovative Approaches to the Management of Acute Lymphoblastic Leukemia Across the Age Spectrum.
    Curran E; Muffly L; Luskin MR
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-11. PubMed ID: 35503981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Have any strategies in Ph-like ALL been shown to be effective?
    Aldoss I; Advani AS
    Best Pract Res Clin Haematol; 2021 Mar; 34(1):101242. PubMed ID: 33762097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
    King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB
    Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of blinatumomab, a novel immunotherapy.
    Newman MJ; Benani DJ
    J Oncol Pharm Pract; 2016 Aug; 22(4):639-45. PubMed ID: 26607163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults.
    Litzow MR; Fielding AK; Luger SM; Paietta E; Ofran Y; Rowe JM; Goldstone AH; Tallman MS; Lazarus HM
    Bone Marrow Transplant; 2017 Dec; 52(12):1592-1598. PubMed ID: 28581459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Advances in the Management of Acute Lymphoblastic Leukaemia.
    Hodby KA; Marks DI
    Curr Treat Options Oncol; 2020 Feb; 21(3):23. PubMed ID: 32095902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of relapsed or refractory acute lymphoblastic leukemia].
    Imai K
    Rinsho Ketsueki; 2017; 58(10):1995-2003. PubMed ID: 28978841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Acute Lymphoblastic Leukemia in Adults: Applying Lessons Learned in Children.
    Aldoss IT; Marcucci G; Pullarkat V
    Oncology (Williston Park); 2016 Dec; 30(12):1080-91. PubMed ID: 27987201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How should we treat a patient with relapsed Ph-negative B-ALL and what novel approaches are being investigated?
    Gökbuget N
    Best Pract Res Clin Haematol; 2017 Sep; 30(3):261-274. PubMed ID: 29050699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.